VolitionRx Ltd. announced that its Nu.Q NETs H3.1 assay has been selected as the exclusive biomarker for DETECSEPS, a French national initiative evaluating early sepsis detection methods. The program, funded through France's 2030 plan with a €6.3 million grant, is led by the IHU SEPSIS and aims to transform emergency care for patients with infection and sepsis risk.
Professor Djillali Annane, Scientific Director of DETECSEPS, stated that combining Volition's biomarker with the NEWS2 clinical score could significantly improve early sepsis identification in emergency settings. He emphasized that H3.1 shows strong correlation with disease severity and provides superior prognostic utility for outcomes including organ failure and mortality compared to established severity scores like APACHE II and SOFA.
Dr. Andrew Retter, Volition's Chief Medical Officer, noted the biomarker delivers results within one hour using the Immunodiagnostic Systems i10 automated analyzer, potentially enhancing emergency decision-making. The company believes earlier sepsis identification could save lives, improve survivor quality of life, and reduce healthcare system burdens.
This selection represents a significant validation of epigenetic approaches to disease detection. Sepsis affects millions globally and remains a leading cause of hospital deaths, with early detection critical for improving outcomes. The French initiative's focus on practical emergency room applications could establish new standards for sepsis management worldwide.
Volition is providing the assay pro-bono for the evaluation, demonstrating commitment to advancing sepsis detection technology. The company's research focuses on developing simple, cost-effective blood tests for various diseases through epigenetic analysis. More information about Volition's work is available at https://www.Volition.com.
The DETECSEPS program's outcomes could influence sepsis protocols beyond France, potentially leading to broader adoption of biomarker-based approaches. As healthcare systems worldwide seek more efficient diagnostic tools, this initiative represents an important step toward standardized, evidence-based sepsis detection methods that balance clinical utility with practical implementation requirements.
